How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle
الأصول والمواضيع المتأثرة
نبرة المقال
التأثير المتوقع على السوق
مسار الأدلة
الأدلة
مصدر التحليل بالذكاء الاصطناعي
المعرّفات التقنية
- وسم المزوّد
- free-analysis-rule-based-analysis
- إصدار التحليل
- free-analysis-rule-based-analysis
- معرّف المقال
- 99222
المصدر الأصلي
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company’s hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look. (Source: Bloomberg)
اقرأ المقال كاملاً على Bloomberg
المقال الأصلي منشور بواسطة Bloomberg في يونيو 23, 2026. التحليل والرؤى المقدمة من AnalystMarkets AI.
أداء هذا النموذج على أخبار مشابهة
Free Analysis Rule Based Analysis · 37,9% صحيحة عبر 66 توقّعاً مُقيَّماً على المؤشرات اطّلع على السجل الكامل